Understand the mechanisms underlying mitophagy-dependent

The gap

Evidence profile

Sourced from the limitations section and future work and future-work section of the source papers, classified as general, spanning 3 journals.

Supporting evidence — 3 representative gaps

• Mitochondrial-targeted therapeutics in oral squamous cell carcinoma: molecular and therapeutic implications (2026) · Frontiers in Medicine · doi

  Intratumoral heterogeneity is a major challenge in the development of effective therapeutic strategies for OSCC. Limited tumor-selective mitochondrial delivery is a significant obstacle to the clinical implementation of mitochondrial-targeted therapeutics. The lack of validated predictive and pharmacodynamic biomarkers is a major limitation in the field.

  generallimitations section
  Keywords: intratumoral heterogeneity major challenge development effective therapeutic strategies
• Targeting mitochondria as a potential therapeutic strategy against radioresistance in cancer (2026) · Frontiers in Oncology · doi

  Emerging evidence positions mitochondria as actionable hubs for radiosensitization, yet several hurdles remain. First, predictive biomarkers—such as ROS responsiveness, Drp1 phosphorylation status, or Bcl−2 family expression profiles—must be validated to stratify patients most likely to benefit. Second, next−generation mitochondrial modulators (e.g., Drpitor1a, Mito−Met10) require rigorous pharmacokinetic and safety evaluation, ideally within tumor−selective nanocarriers to spare normal tissues. Third, ratio- nal combination regimens should exploit synthetic lethal interac- tions (e.g., Pol g inhibition in MLH1−deficient tumors) and synergies with immunotherapy (cGAS/STING activation). Fourth, real−time monitoring of mitochondrial dynamics and metabolic flux using advanced imaging or liquid biopsies could guide adaptive radiotherapy. Finally, clinical trials must address optimal sequenc- ing, dosing, and fractionation when pairing mitochondrial agents with radiation. Conquering radioresistance will likely demand personalized, mitochondria−targeted adjuncts that convert refrac- tory tumors into radiosensitive phenotypes. Mitochondria orchestrate radioresistance through intercon- nected mechanisms: metabolic reprogramming (enhanced OXPHOS, glycolysis, and PPP flux), ROS regulation (upregulated antioxidant enzymes, GSH, NRF2), dynamic remodeling (Drp1−mediated fission, OPA1/Mfn fusion), apoptotic dysregulation (Bcl−2 family overexpression, IAP−mediated caspase blockade), and mtDNA repair (Pol g, SSBP1, EXOG). These adaptations collectively enable cancer cells to survive radiation −induced genotoxic and oxidative stress, repair damage, and evade cell death.

  generalfuture workevidence 5/5
  Keywords: mitochondria mitochondrial family must likely tumors metabolic radiation radioresistance mediated repair emerging evidence positions actionable
• Mitophagy-dependent mitochondrial DNA release links ionizing radiation to immunogenic cell death in pancreatic cancer (2026) · Cell Death Discovery · doi

  Further studies are needed to understand the mechanisms underlying mitophagy-dependent mitochondrial DNA release and its role in radiation-induced immunogenicity. Research should investigate the potential of modulating mitochondrial dynamics to enhance radiosensitivity and immunogenic potential in pancreatic cancer.

  generalfuture-work sectionevidence 5/5
  Keywords: further studies needed understand mechanisms underlying mitophagy-dependent mitochondrial

Questions about this gap